Neurimmune Holding

What Neurimmune Holding does

Neurimmune Holding AG (Neurimmune AG) is a privately held, clinical-stage biopharmaceutical company founded in 2006 as a University of Zurich spin-off by Roger Nitsch, Christoph Hock, and Jan Grimm, headquartered in Schlieren/Zurich, Switzerland. The company develops fully human monoclonal antibody therapeutics that selectively target pathological, misfolded protein conformations while sparing normal physiological forms, a mechanism it brands as "amyloid depletion." Its core discovery engine is the proprietary Reverse Translational Medicine (RTM™) platform, which derives antibody genetic blueprints from immune memory cells of elderly human subjects to identify high-affinity, low-immunogenicity candidates. The clinical-stage pipeline includes cliramitug (Phase 3 in ATTR-CM, licensed to AstraZeneca/Alexion), AP-101 (Phase 2 in ALS, via the AL-S Pharma joint venture with TVM Capital Life Science), NG004 (Phase 1 in spinal cord injury, via Novago Therapeutics), and preclinical programs NI009 (AL amyloidosis, also licensed to AstraZeneca), NI101B3 (next-generation bispecific for Alzheimer's disease), and NI504 (neurodegeneration, partnered with Ono Pharmaceutical). Selectivity for disease-associated conformations is the unifying scientific thesis across all assets.

Neurimmune operates a partner-driven commercialization model rather than building internal sales infrastructure. Revenue is generated through licensing and collaboration agreements structured around upfront payments, contingent development and regulatory milestones, and tiered royalties on net sales. The strategic anchor is Alexion, AstraZeneca Rare Disease, which holds global development and commercialization rights for cliramitug (deal announced 2022) and expanded in December 2025 to include NI009 with up to $780 million in potential milestones plus royalties. Secondary partnerships include TVM Capital Life Science (co-financing AL-S Pharma for AP-101), Ono Pharmaceutical (NI504), Pueros Bioventures, and Novago Therapeutics (NG004). The company presents itself as entrepreneurial and independent, retaining autonomy over early discovery while licensing late-stage risk and commercialization to larger pharma counterparties.

Customer concentration is high by structure: with no approved products, near-term revenue depends almost entirely on AstraZeneca's execution on cliramitug and NI009, plus the AL-S Pharma / TVM Capital vehicle for AP-101. Operating geographies are disclosed only at the Switzerland/EU level, though clinical trials and commercialization reach globally via AstraZeneca. The company is led by the three co-founders in the CEO, CMO, and CSO seats, supplemented by a board including former Biogen R&D leader Alfred Sandrock and senior executives with prior roles at Pfizer, J&J, Roche, and ETH. Scientific credibility is supported by peer-reviewed publications in NEJM, Nature, and Science Translational Medicine, including foundational work on aducanumab.

Name

Neurimmune Holding

Legal name

Neurimmune AG

Website

https://neurimmune.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

51–100 employees

Short description

Neurimmune is a Swiss clinical-stage biopharmaceutical company developing fully human monoclonal antibodies that selectively deplete misfolded proteins, with a pipeline led by cliramitug (Phase 3 ATTR-CM, licensed to AstraZeneca), AP-101 (Phase 2 ALS), and preclinical candidates in Alzheimer's and AL amyloidosis, partnered with AstraZeneca, TVM Capital, and Ono Pharmaceutical.

Ownership category

akta.pro rank

Product category

Biopharmaceutical Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Recombinant Protein Therapeutics (enzymes, hormones, growth factors) (HLAAAAAB)

akta.pro secondary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

Keywords

• Antibody therapeutics
• Biopharmaceutical development
• Protein aggregation diseases
• Amyloid depletion therapy
• Clinical stage biotech

Headquarters

HQ city

Schlieren

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Partnership and Licensing Revenue: Neurimmune engages in selective strategic partnerships for late-stage clinical development and commercialization, while retaining autonomy over early innovation and portfolio direction. The company receives upfront payments, milestone payments, and royalties on net sales from partnership agreements.
2. Collaboration Milestone Payments: Non-dilutive financing through partnership agreements including upfront payments and potential contingent milestone payments upon achievement of development, regulatory, and commercial milestones.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Core offering

Neurimmune is a clinical-stage biopharmaceutical company that discovers and develops fully human monoclonal antibody therapeutics for protein aggregation diseases using its proprietary Reverse Translational Medicine (RTM™) platform. Its products selectively target and deplete misfolded, pathological protein aggregates (e.g., ATTR amyloid, SOD1, amyloid-beta, light chain fibrils, Nogo-A) while sparing normal physiological proteins, with a pipeline spanning ATTR cardiomyopathy, ALS, Alzheimer's disease, AL amyloidosis, spinal cord injury, and other neurodegenerative indications. Late-stage development, manufacturing, and commercialization are executed through strategic licensing and co-development partners such as AstraZeneca (Alexion) and AL-S Pharma.

Differentiator

Problem solved

Functional benefit

Products and services

• Cliramitug (formerly ALXN2220, NI006) Recombinant human monoclonal IgG1 antibody that exclusively targets with high affinity the disease-associated amyloid conformation of transthyretin (TTR) while sparing physiological TTR, designed to deplete amyloid deposits in ATTR cardiomyopathy (ATTR-CM) through immune-mediated phagocytosis; Phase 3 via AstraZeneca.
• AP-101 Recombinant human antibody designed to selectively deplete toxic, misfolded forms of SOD1 while preserving the protective function of physiological SOD1, targeting misfolded SOD1 to disrupt disease progression in amyotrophic lateral sclerosis (ALS); Phase 2 via AL-S Pharma AG.
• NG004 Human antibody blocking Nogo-A function, one of the most potent inhibitors of nerve fiber regeneration in the central nervous system, designed to induce neuronal regeneration for treatment of spinal cord injury; Phase 1 via Novago Therapeutics.
• NI009 Human monoclonal antibody designed to target and deplete light chain fibrils and deposits from affected tissues and organs in light chain (AL) amyloidosis, exhibiting broad activity against amyloids of diverse lambda light chain subtypes; preclinical, partnered with AstraZeneca.
• NI101B3 Next-generation bispecific amyloid-beta targeting antibody with improved blood-brain barrier penetration, engineered to selectively deplete amyloid-beta aggregates in the brain for treatment of Alzheimer's disease; preclinical.
• NI504 Human monoclonal antibody targeting neurodegeneration, partnered with Ono Pharmaceutical; preclinical-stage.

Quantifiable outcome

• Phase 1 study published in NEJM demonstrated favorable safety profile with no apparent dose-limiting toxic effects or drug-related serious adverse reactions at highest doses tested
• +2 more outcomes

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature5 records

Partnerships

Five partnerships are on record, tiered minor and core.

• ACCESS-AD ConsortiumminorStrategic or Co-development Partner · 13 January 2026European initiative to accelerate implementation of scientific innovations for Alzheimer's disease management in real-world health systems. Consortium brings together academic institutions, industry partners, SMEs and patient organisations. Neurimmune contributes to development of advanced imaging and blood-based digital biomarkers with five-year programme funding from European Commission.
• Alexion, AstraZeneca Rare DiseasecoreStrategic or Co-development Partner · 4 December 2025Neurimmune entered into an exclusive global collaboration and license agreement with Alexion, AstraZeneca Rare Disease for cliramitug (ATTR-CM) in 2022. In December 2025, this collaboration was expanded to include NI009 for AL amyloidosis. Neurimmune receives upfront payments and potential milestone payments of up to $780 million plus tiered royalties on net sales. Neurimmune handles preclinical and early clinical development while AstraZeneca handles further development, manufacturing, and commercialization.
• Ono PharmaceuticalminorStrategic or Co-development PartnerOne of the selective strategic partnerships Neurimmune engages in for late-stage clinical development and commercialization, mentioned alongside AstraZeneca, TVM Capital, and Pueros Bioventures.
• Novago TherapeuticscoreStrategic or Co-development PartnerStrategic partnership with Novago Therapeutics, a spin-off from University of Zurich, to discover and develop human antibodies targeting Nogo-A for spinal cord injury. NG004 is being developed by Novago Therapeutics under this partnership.
• AL-S Pharma AGcoreStrategic or Co-development PartnerSwiss-based clinical-stage biotech company co-founded and co-owned by Neurimmune and TVM Capital Life Science to develop AP-101 for ALS treatment. Based in Zurich, Switzerland with seasoned team spanning drug discovery, translational research, and clinical development.

Scale indicators4 records

Recent moves8 records

Expansion highlights5 records

Direct peers

• BridgeBio Pharma: Commercial-stage biopharma whose acoramidis (Attruby) is an approved TTR stabilizer for ATTR-CM. Direct competitor to Neurimmune's cliramitug in the same indication; demonstrates the ATTR-CM commercial opportunity but also establishes competitive intensity.
• Alnylam Pharmaceuticals: Commercial-stage biopharma with leading RNAi therapeutics for transthyretin amyloidosis (Onpattro, Amvuttra). Directly competing with Neurimmune's cliramitug in ATTR-CM via an alternative mechanism (silencing TTR production vs. depleting deposited amyloid) — overlapping indication and patient population.
• Denali Therapeutics: Clinical-stage biotech engineering antibody-based therapeutics for neurodegenerative diseases including Alzheimer's, ALS, and Parkinson's. Comparable in antibody platform approach, CNS delivery focus, and protein aggregation disease pipeline; also partnered with major pharma (Biogen, Takeda, Sanofi).
• Prothena Corporation: Clinical-stage biotech developing antibody-based therapeutics targeting protein misfolding and aggregation diseases including ATTR amyloidosis (acoramidis was partnered with BridgeBio), Alzheimer's, and Parkinson's. Directly comparable to Neurimmune in platform-mechanism (antibody-based depletion of misfolded proteins) and disease focus (ATTR-CM).

Broad incumbents

• Biogen: Global biopharma and Neurimmune's original major investor ($150M in 2017) and licensee of aducanumab (developed from Neurimmune's RTM platform). Competes in Alzheimer's (Leqembi, Aduhelm) and broader neuro; uniquely comparable as both platform progenitor and commercial-stage reference point.
• Regeneron Pharmaceuticals: Large-cap biopharma with a leading antibody platform (VelocImmune) and clinical programs in ophthalmology, immunology, and neuro. Comparable as a platform-based antibody developer with multiple partnered programs; relevant valuation/scale reference for what a mature antibody-platform company can become.
• Ionis Pharmaceuticals: Antisense oligonucleotide platform company with approved TTR amyloidosis drug (Tegsedi, partnered with Akcea). Indirect competitor in ATTR via different modality and broad neuro pipeline including ALS — relevant comparable for pipeline breadth and amyloidosis commercial dynamics.
• Voyager Therapeutics: Clinical-stage neuro-focused biotech led by Alfred W. Sandrock (Neurimmune board director). Overlapping executive network and CNS/neurodegenerative disease focus; comparable in stage and mission though differentiated by gene therapy vs. antibody modality.

Emerging players

• Acumen Pharmaceuticals: Clinical-stage biotech developing antibody therapeutics targeting toxic soluble amyloid-beta oligomers for early Alzheimer's disease. Compares to Neurimmune's NI101B3 (anti-amyloid-beta bispecific) in target disease and amyloid-depletion mechanism, though narrower in pipeline breadth.
• Wave Life Sciences: Clinical-stage biotech developing RNA editing and antisense therapies for neurodegenerative diseases including ALS (with collaborators including Takeda). Comparable in clinical-stage neuro pipeline and partnership-driven model; modality differs (oligonucleotide vs. antibody).

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/neurimmune
• LinkedInlinkedin.com/company/neurimmune-holding-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles8 records

Subsidiaries2 records

Funding overview

Funding rounds1 record

Investors1 record

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments3 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Neurimmune Holding